Browsing Tag
nab-paclitaxel
3 posts
Corcept Therapeutics (NASDAQ: CORT) climbs 7% as Lifyorli launch and analyst upgrades drive cortisol re-rating
Corcept turned a stress hormone into an ovarian cancer drug. Lifyorli is launching fast and analysts are chasing, but a premium multiple prices in a lot.
Corcept Therapeutics (CORT) stock in focus as ROSELLA survival data strengthen Lifyorli launch in ovarian cancer
Corcept Therapeutics strengthened its Lifyorli launch with new ROSELLA survival data. Read what this means for CORT stock and ovarian cancer treatment.
Could repeated VCN-01 dosing overcome long-standing survival barriers in metastatic PDAC?
Theriva Biologics advances VCN-01 into phase 3 for metastatic pancreatic cancer with FDA and EMA guidance. Discover what this means for trial execution and survival outcomes.